134 related articles for article (PubMed ID: 19785973)
1. Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
Rostain AL
Curr Psychiatry Rep; 2009 Oct; 11(5):341-2. PubMed ID: 19785973
[No Abstract] [Full Text] [Related]
2. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
3. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
Jun A
Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
[No Abstract] [Full Text] [Related]
4. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
5. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
6. Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis.
Bruno C; Zoega H; Gillies MB; Havard A; Coghill D; Pearson SA; Brett J
Aust N Z J Psychiatry; 2023 Jul; 57(7):1073-1076. PubMed ID: 37122132
[No Abstract] [Full Text] [Related]
7. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Brams M; Giblin J; Gasior M; Gao J; Wigal T
Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine.
Blick SK; Keating GM
Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
12. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials.
Surman CB; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):903-8. PubMed ID: 21824454
[TBL] [Abstract][Full Text] [Related]
13. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
Weisler R; Young J; Mattingly G; Gao J; Squires L; Adler L;
CNS Spectr; 2009 Oct; 14(10):573-85. PubMed ID: 20095369
[TBL] [Abstract][Full Text] [Related]
15. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
Steer C; Froelich J; Soutullo CA; Johnson M; Shaw M
CNS Drugs; 2012 Aug; 26(8):691-705. PubMed ID: 22762726
[TBL] [Abstract][Full Text] [Related]
16. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
Weber J; Siddiqui MA
CNS Drugs; 2009; 23(5):419-25. PubMed ID: 19453202
[TBL] [Abstract][Full Text] [Related]
17. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
[TBL] [Abstract][Full Text] [Related]
18. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
19. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
